The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Open accessAbstract
Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung. Most CF mutations either reduce the number of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both. There are currently no approved therapies that target CFTR. Here we describe the in vitro pharmacology of VX-770, an orally bioavailable CFTR potentiator in clinical development for the treatment of CF. In recombinant cells VX-770 increased CFTR channel open probability (P o ) in both the F508del processing mutation and the G551D gating mutation. VX-770 also increased Cl − secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈10-fold, to ≈50% of that observed in HBE isolated from individuals without CF. Furthermore, VX-770 reduced excessive Na + and fluid absorption to prevent dehydration of the apical surface and increased cilia beating in these epithelial cultures. These results support the hypothesis that pharmacological agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
Welsh, M. J., & Smith, A. E. (1993) · Cell · doi:10.1016/0092-8674(93)90353-r · Cited by 1,485
Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81724-9 · Cited by 1,169
The diagnosis of cystic fibrosis: A consensus statement
Rosenstein, B. J., & Cutting, G. R. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70344-0 · Cited by 1,086
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Chloride impermeability in cystic fibrosis
Quinton, P. M. (1983) · Nature · doi:10.1038/301421a0 · Cited by 767
Davis, P. B., Drumm, M., & Konstan, M. W. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.5.8912731 · Cited by 764
Increased Bioelectric Potential Difference across Respiratory Epithelia in Cystic Fibrosis
Knowles, M., Gatzy, J., & Boucher, R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112173052502 · Cited by 608
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
Castellani, C., Cuppens, H., Macek, M., Cassiman, J. J., Kerem, E., Durie, P., Tullis, E., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 601
Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 538
Ma, T., Thiagarajah, J. R., Yang, H., Sonawane, N. D., Folli, C., Galietta, L. J. V., & Verkman, A. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216112 · Cited by 536
Van Goor, F., Straley, K. S., Cao, D., González, J., Hadida, S., Hazlewood, A., Joubran, J., Knapp, T., Makings, L. R., Miller, M., et al. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00169.2005 · Cited by 512
Self-citationAbnormal Ion Permeation Through Cystic Fibrosis Respiratory Epithelium
Knowles, M. R., Stutts, M. J., Spock, A., Fischer, N., Gatzy, J. T., & Boucher, R. C. (1983) · Science · doi:10.1126/science.6308769 · Cited by 485
Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties
Sheppard, D. N., Rich, D. P., Ostedgaard, L. S., Gregory, R. J., Smith, A. E., & Welsh, M. J. (1993) · Nature · doi:10.1038/362160a0 · Cited by 467
Poulsen, J. H., Fischer, H., Illek, B., & Machen, T. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5340 · Cited by 420
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study
McKone, E. F., Emerson, S. S., Edwards, K. L., & Aitken, M. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13368-5 · Cited by 397
Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., Jorissen, M., Droogmans, G., Reynaert, I., Goossens, M., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci639 · Cited by 397
Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis
Quinton, P. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61162-9 · Cited by 381
Lazarowski, E. R., Boucher, R. C., & Harden, T. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003255200 · Cited by 314
Knowles, M. R., Paradiso, A. M., & Boucher, R. C. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.4-445 · Cited by 308
Noone, P. G., Zhou, Z., Silverman, L. M., Jowell, P. S., Knowles, M. R., & Cohn, J. A. (2001) · Gastroenterology · doi:10.1053/gast.2001.29673 · Cited by 307
Relative ion permeability of normal and cystic fibrosis nasal epithelium.
Knowles, M., Gatzy, J., & Boucher, R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110894 · Cited by 286
All‐digital image capture and whole‐field analysis of ciliary beat frequency
Sisson, J. H., Stoner, J. A., Ammons, B. A., & Wyatt, T. A. (2003) · Journal of Microscopy · doi:10.1046/j.1365-2818.2003.01209.x · Cited by 280
Cystic fibrosis: a disease of vulnerability to airway surface dehydration
Boucher, R. C. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.05.001 · Cited by 273
ATPase Activity of the Cystic Fibrosis Transmembrane Conductance Regulator
Li, C., Ramjeesingh, M., Wang, W., Garami, E., Hewryk, M., Lee, D., Rommens, J. M., Galley, K., & Bear, C. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28463 · Cited by 267
Berger, H. A., Anderson, M. P., Gregory, R. J., Thompson, S., Howard, P. W., Maurer, R. A., Mulligan, R., Smith, A. E., & Welsh, M. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115450 · Cited by 259
REGULATION OF NORMAL AND CYSTIC FIBROSIS AIRWAY SURFACE LIQUID VOLUME BY PHASIC SHEAR STRESS
Tarran, R., Button, B., & Boucher, R. C. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.072304.112754 · Cited by 243
Altered Fluid Transport Across Airway Epithelium in Cystic Fibrosis
Jiang, C., Finkbeiner, W. E., Widdicombe, J. H., McCray, P. B., & Miller, S. S. (1993) · Science · doi:10.1126/science.8211164 · Cited by 216
Koch, C., Cuppens, H., Rainisio, M., Madessani, U., Harms, H. K., Hodson, M. E., Mastella, G., Navarro, J., Strandvik, B., McKenzie, S. G., et al. (2001) · Pediatric Pulmonology · doi:10.1002/1099-0496(200101)31:1<1::aid-ppul1000>3.0.co;2-t · Cited by 200
SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia
Bertrand, C. A., Zhang, R., Pilewski, J. M., & Frizzell, R. A. (2009) · Journal of General Physiology · doi:10.1085/jgp.200810097 · Cited by 166
Self-citationPedemonte, N., Sonawane, N. D., Taddei, A., Hu, J., Zegarra‐Moran, O., Suen, Y. F., Robins, L. I., Dicus, C. W., Willenbring, D., Nantz, M. H., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.010959 · Cited by 155
Briel, M., Greger, R. F., & Kunzelmann, K. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.825bp.x · Cited by 128
Morán, Ó., Galietta, L. J. V., & Zegarra‐Moran, O. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4422-3 · Cited by 126
Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein
Illek, B., Zhang, L., Lewis, N. C., Moss, R. B., Dong, J.-Y., & Fischer, H. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.4.c833 · Cited by 121
Lung Disease Associated with the IVS8 5T Allele of the CFTR Gene
Noone, P. G., Pue, C. A., Zhou, Z., Friedman, K. J., Wakeling, E. L., Ganeshananthan, M., Simon, R. H., Silverman, L. M., & Knowles, M. R. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.2003160 · Cited by 119
Myerburg, M. M., Butterworth, M. B., McKenna, E. E., Peters, K. W., Frizzell, R. A., Kleyman, T. R., & Pilewski, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606449200 · Cited by 109
Self-citationChoi, J. Y., Joo, N. S., Krouse, M. E., Wu, J. V., Robbins, R. C., Ianowski, J. P., Hanrahan, J. W., & Wine, J. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31992 · Cited by 99
Self-citationHyposecretion, Not Hyperabsorption, Is the Basic Defect of Cystic Fibrosis Airway Glands
Joo, N. S., Irokawa, T., Robbins, R. C., & Wine, J. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512766200 · Cited by 97
Self-citationSchreiber, R., Hopf, A., Mall, M. A., Greger, R. F., & Kunzelmann, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5310 · Cited by 95
Zabner, J., Couture, L. A., Smith, A. E., & Welsh, M. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.5-585 · Cited by 91
Jiang, C., O'Connor, S. P., Armentano, D., Berthelette, P., Schiavi, S. C., Jefferson, D. M., Smith, A., Wadsworth, S., & Cheng, S. H. (1996) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1996.271.4.l527 · Cited by 27
Effect of Cytosolic pH on Epithelial Na+ Channel in Normal and Cystic Fibrosis Sweat Ducts
Reddy, M. M., Wang, X. F., & Quinton, P. (2008) · The Journal of Membrane Biology · doi:10.1007/s00232-008-9126-4 · Cited by 25
Research works printed but not linked: 7
- F Van Goor, S Hadida, PDJ Grootenhuis, Pharmacological rescue of mutant CFTR funciton for the treatment of cystic fibrosis. Topics Med Chem 3, 29 (2008).
- FJ Accurso, et al., Interim results of phase 2a study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatr Pulmonol 31, 1 (2008).
- 10.1038/sj.bjp.0705597 · doi:10.1038/sj.bjp.0705597
- 10.1016/S0006-3495(97)78686-7 · doi:10.1016/s0006-3495(97)78686-7
- 10.1016/S0140-6736(98)05447-6 · doi:10.1016/s0140-6736(98)05447-6
- 10.1007/s00424-002-0956-0 · doi:10.1007/s00424-002-0956-0
- 10.1165/rcmb.2002-0104OC · doi:10.1165/rcmb.2002-0104oc
Cited by
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Self-citationZhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,082
Metadata
- Authors
- Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., Zhou, J., McCartney, J., Arumugam, V., Decker, C., Yang, J., Young, C., Olson, E. R., Wine, J. J., Frizzell, R. A., Ashlock, M., & Negulescu, P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-11-03
- Volume
- 106
- Issue
- 44
- Pages
- 18825-18830
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2035131077
- Cited by
- 1,228
- References
- 44
- FWCI
- 36.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.